Catalyst Dossier · compiled by CeliA 🧫
PFIZER (PFE)
Pharmaceutical Preparations · market cap $143.7B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-19 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Pfizer is a large-cap, vertically integrated pharmaceutical company with $137B market cap, ~75,000 employees, and $62.6B in revenues (2025), carrying $62.8B net debt largely a legacy of pandemic-era M&A. The company trades at ~$24 with a diversified pipeline spanning oncology, immunology, vaccines, and metabolic disease, with several high-importance catalysts clustered in H2 2026.
The catalyst path
- 2026-10-19 (est.)Phase 2 · PF-07264660imp 7/10
- 2026-11-29 (est.)Phase 3 · Rimegepantimp 9/10
- 2026-12-02 (est.)Phase 3 · Ritlecitinib higher doseimp 9/10
- 2026-12-04 (est.)Phase 3 · VLA15imp 9/10
- 2026-12-11 (est.)Phase 2 · disitamab vedotinimp 7/10
- 2026-12-25 (est.)Phase 2 · Ritlecitinib 50 mgimp 7/10
- 2026-12-30 (est.)Phase 3 · ARV-471 (PF-07850327)imp 9/10
- 2026-12-30 (est.)Phase 2 · ARV-471imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DVS-233 SR (desvenlafaxine sustained release ) | Phase 3 | Major Depressive Disorder |
| PF-08653945 | Phase 2 | Overweight |
| Insulin Lispro | Phase 3 | Diabetes Mellitus |
| Cyclosporine A | Phase 3 | Renal Transplantation |
| PF-06826647 | Phase 2 | Psoriasis |
| 13 valent pneumococcal conjugate vaccine with Polysorbate 80 | Phase 3 | Vaccines, Pneumococcal |
| Meropenem | Phase 3 | Complicated Intra-abdominal Infections |
| MET097 | Phase 3 | Obesity |
| RSVpreF (Group 1) | Phase 3 | RSV |
| Imipenem-cilastatin | Phase 3 | Skin Infection |
| Diclofenac | Phase 3 | Spondylitis, Ankylosing |
| PF-07850327, ARV-471, vepdegestrant | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer |
| CP-690-550 | Phase 2 | Arthritis, Rheumatoid |
| SU-011,248 | Phase 2 | Kidney Neoplasms |
| Pediacel | Phase 3 | Vaccines, Pneumococcal |
| Pemetrexed/Cisplatin | Phase 3 | NSCLC (Non-small Cell Lung Cancer) |
| Multivalent Pneumococcal Vaccine - Formulation 1 | Phase 2 | Pneumococcal Disease |
| 0.04 mg/kg CpG 7909 | Phase 2 | Carcinoma, Breast |
| PF-04217329 - Lowest Dose | Phase 2 | Primary Open-Angle Glaucoma |
| bazedoxifene 20 mg/ conjugated estrogens 0.45 mg | Phase 3 | Menopause |
Price & technical context
3-month
+10.6%
6-month
+2.9%
12-month
+14.9%
52-wk range
$23.60–$29.02
vs 50-day MA
+3.9%
vs 200-day MA
+5.5%
Realized vol
23.5%
Max drawdown
-28.5%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PFE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.